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EDITORIAL 
Porphyria and Pseudoporphyria 
During t he past two decades there have been increasing 
reports of patients manifesting clinical signs of porphyria 
cutanea tarda (PCT), specifically, increased skin fragility 
and bulla formation of exposed areas. A subset of t his 
group relates a history of ingesting certain drugs (nali-
dixic acid, furosemide, and tetracycline) or are patients 
with chronic renal failure, some of whom were undergo-
ing hemodialysis. Despite the s imilarity of t he cutaneous 
findings in t hese groups of patients to those with por-
phyria cutanea tarda, there has been no detectable ab-
normality noted in porphyrin-heme biochemistry leading 
t o the ir designation as having "pseudoporphyria. " 
In this issue of the Journal, Keane, Pearson, and 
Malkinson report their findings in developing an exper-
imental animal model for the drug-related type of pseu-
doporphyria. While the doses of the drug (nalidixic acid), 
and radiant energy (UV A), required to elicit the patho-
logic responses are high, t he pathologic changes identi-
fied do appear to represent a subepidermal blister, sug-
gesting a relationship to pseudoporphyria. However, 
none of t he biochemical changes found in the urine of 
patients with porphyria cutanea tarda was observed in 
any of the animals. It should also be emphasized that 
t his an imal model does not address t he form of pseudo-
porphyria t hat accompanies chronic renal failure and 
hemodialysis. 
PCT continues to be the most commonly recognized 
of t he cutaneous porphyrias in the United States, with 
an estimated incidence of 1:25,000 [1]. It was first defin-
itively described by W aldenstrom in 1937 [2] and is 
characterized biochemically by the urinary excretion of 
increased amounts of uroporphyrin and, to a lesser de-
gree, coproporphyrin in t he urine of affected patients 
(usually in a ratio of 5:1) . Increased amounts of uropor-
phyrin also occur in the plasma and feces. There are at 
least two different types of PCT associated with virtually 
identical clinical features and patterns of abnormal por-
phyrin excretion. One type is inherited as an autosomal 
dominant trait and is characterized by decreased activity 
of the enzyme uroporphyrinogen decarboxylase (URO-
D) in the liver and in the red blood cells (RBC) of affected 
individuals. The second type is acquired and is associated 
with a similar decrease in hepatic URO-D activity; how-
ever, in contrast to the inherited form, there appears to 
be normal RBC URO-D activity. The second type usua lly 
occurs in patients exposed to ethanol , estrogens, or en-
vironmental chemicals such as certain chlorinated hy-
drocarbons. The latter compounds have been shown to 
inhibit the catalytic activity of URO-D without altering 
the amount of immunoreactive enzyme protein [3]. In 
both types of PCT, deficient enzyme activity results in 
an identical excretory pattern of porphyrins character-
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ized by an increase in the more hydrophilic, highly car-
boxylated porphyrins in the urine, with predominance of 
the type I isomer. Another diagnostic biochemical finding 
in PCT is the increased fecal excretion of isocopropor-
phyrin which occurs as a direct consequence of the de-
creased URO-D. In both types of PCT, hepatic iron 
deposition (siderosis) is a constant feature and, clinically, 
t he intake of excessive iron may be an exacerbating 
factor. 
In contrast to PCT, pseudoporphyria has no known 
abnormality in heme biosynthesis and porphyrin excre-
tion is completely normal. The occurrence of cutaneous 
lesions that closely mimic PCT in normal individuals 
with no biochemical abnormality in porphyrin metabo-
lism has been known but unexplained since 1964. At that 
time, Zelickson reported phototoxic reactions in patients 
following the use of nalidixic acid [ 4]. Clinically, the skin 
lesions were indistinguishable from those observed in 
patients with PCT. Since that initial observation, similar 
reports regarding nalidixic acid have appeared [5,6]. Ad-
ditional drugs incriminated in mediating this type of 
phototoxicity include tetracycline [7] and furosemide 
[8]. In no case has any type of biochemical abnormality 
in heme synthesis or porphyrin precursors been reported 
with any of these medications. 
The cutaneous changes common to all patients with 
drug-related pseudoporphyria, regardless of the medica-
tion involved, include increased bruisability following 
minor trauma predominantly on the dorsa of the hands, 
erythema, and vesicles and bullae on the face, fingers , 
and hands. The prognosis in the affected patients is 
excellent if t he drug is discontinued; however, clinical 
lesions have persisted for several months following ces-
sation of the medication in some patients. Exposure to 
sunlight appears to be a contributing or aggravating 
factor in most cases. However, all phototests and pho-
topatch tests have been reported as negative. 
A second type of pseudoporphyria which appears com-
pletely unrelated to exposure to drugs was first described 
by Gilchrest et al in 1975 [9] . This has been called the 
"bullous dermatosis of hemodialysis." At about t he same 
time, Korting also observed several patients with renal 
failure who had cutaneous changes that closely mimicked 
PCT and coined t he term "pseudoporphyria" [10]. In an 
overwhelming number of patients with "pseudoporphy-
ria" associated with renal fai lure, analysis for urinary, 
feca l, and plasma porphyrins have been normal; exposure 
to sunlight seems to be a contributing or aggravating 
factor in many patients [11]. Just as in patients with 
drug-induced pseudoporphyria, all phototests and pho-
topatch tests in the patients with renal failure were 
reported as negative. 
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TABLE I. Comparative features of PCT and pseudopo rphyria 
Drugs 
Ethanol 
Estrogens 
PCT 
Environmenta l chemicals 
Hexachlorobenzene 
Polyhalogenated hydrocarbons 
Pseudoporphyria 
Drugs 
Nalidixic ac id 
Tetracycline 
Furosemide 
Systemic disease 
Chronic renal failure 
Hemodialysis 
It is important to emphasize that some patients sus-
pected clinically to have pseudoporphyria associated with 
renal failure may actually have PCT, as determined by 
increased plasma porphyrins [1 2] or by decreased URO-
D [13], and that patients receiving hemodialysis in 
chronic renal failure may have elevated plasma porphy-
rins with no cutaneous lesions [14,15]. Obviously this 
group of patients requires further study regarding the 
relationship between biochemical porphyrinemia and 
skin lesions as well as the role , if any, of hemodialysis in 
producing t he syndrome. 
T reatment of PCT, Pseudoporphyria, and PCT in 
Patients with Chronic Renal Failure 
The primary t herapeutic approach to PCT and pseu-
doporphyria is the elimination of exposure to the offend-
ing agents whenever possible. These are listed in Table 
I. 
The early reports of patients with drug-induced pseu -
doporphyria indicate that skin lesions can persist for 
many months after discontinuing the offending agent; 
consequent ly, it may be difficult to identify t he cause of 
drug-induced pseudoporphyria or to assess the effective-
ness of any t herapeutic regimen for this disorder. 
Treatment of PCT 
The majority of male patients developing PCT relate 
a history of excessive alcohol consumption while the 
majority of females relate a history of receiving estrogen 
in the form of oral contraceptives as a hormonal supple-
ment. Selected males with prostatic carcinoma who have 
rece ived adjunctive stilbesterol t herapy have also devel -
oped PCT. 
The three major therapies employed for PCT are phle-
botomy, oral administration of the antimalarial drugs, 
chloroquine and hydroxychloroquine, or a combination 
of t hese modalities. 
Over the past 15 years, our photobiology unit has had 
considerable experience with repeated phlebotomies. In 
a group of 40 patients who received an average of slightly 
more than five such treatments during a 2- to 3-week 
period of hospitalization , their blood hemoglobin de-
creased from 15 to 11 g/dl [16]. Urinary porphyrins 
decreased significantly after three months, while im-
provement in the clinical manifestations occurred within 
six months. The duration of clinical remission in this 
series of patients averaged 30 months. 
Malkinson and Levitt [17] studied the therapeutic 
response of six patients with classical PCT to hydroxy-
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chloroquine for treatment periods ranging from 5 to 13 
months. There was an excellent response to therapy 
comparable to t hat seen with phlebotomy. When exac-
erbations occurred after remission , retreatment of pa-
tients usually achieved good results. 
Recently both modalities were compared. Sixty-one 
pat ients were reported in 1983 by Cainelli et a! to have 
received a 1-year course of either hydroxychloroquine 
(200 mg) twice weekly or phlebotomies (400 ml whole 
blood) twice monthly [18] . Both groups showed equal 
and excellent clinical improvement. The degree of bio-
chemical improvement was substantially better in t h e 
hydroxychloroquine-treated group, but liver disease, as 
determined by serial biopsies, appeared to progress more 
in the group treated with the antimalarials. Although 
both modalities are effective, additional numbers of cases 
are needed to decide which is preferable. 
Treatment of Pseudoporphyria 
There is no satisfactory treatment of this disorder aside 
from improvement in renal function and reduced fre-
quency of hemodialysis. 
Treatment of PCT in Patients with Chronic Renal 
Failure 
Repeated phlebotomy has been advocated but this is 
often not feasible because of coexisting anemia in t he 
majority of patients with chronic renal failure [ 19]. 
Plasma exchange has proved successful in at least one 
patient [20]. 
Leonard C. Harber, M.D. 
David R. Bickers, M.D. 
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